chrisvoncsefalvay/vaers-outcomes huggingface dataset:
To clarify the vaccincations listed above, I know our son received HepA, Hib, MMR, &Varicella on 8/28/17. I'm not certain which Hep A, Hib, etc each of the shots was as identified above. The information the clinic gave us did not specify those details. Our son received his vaccinations at his one year check up on 8/28/17 in the morning. On 8/30/17 he woke up after having been put to bed, covered in sweat. We turned a fan on him, opened his window, and checked him again in an hour and saw he was still sweating heavily. We took him to the ER and were told it was probably just a reacation to his vaccinations but that he looked fine.  He was fine the following day (8/31), however that night he was up every hour to hour and a half screaming (he typically sleeps through the night without waking).  I woke up with him at 5 am on 9/1 and realized at that time he had a fever. We started to give him Tylenol and coninued throughout the day on Friday.  He was crabby, tired, and not himself all day.  Whenever the Tylenol wore off, his fever came back.  This continued through Friday night and into Saturday.  Saturday afternoon (9/2) he woke up from a nap with a fever that was over 104 degrees. We immediately gave him more Tylenol, but it didn't bring the fever down.  We called an on call nurse and were advised to bring him back to urgent care/ER.    Upon arrival, we were told that the fever was too high to be a reaction to a vaccine. They checked our son over (eyes, ears, nose, listened to his chest and heart, etc).  They couldn't see anything so they ordered chest x-rays and a strep test.  Everything came back clear so we were told it was a reaction to one of the live immunizations he received on Monday.  All day Sunday (9/3) he was tired, crabby, and refused to eat or drink.  On Monday morning (9/4) he started to eat and play again, however he also broke out in a rash on the back of his neck.  The rash spread to his head, stomach, and back over the course of the next two days.  Finally on Wed, (9/6) we started to see the rash go away and his attitude, appetite, etc all returned to normal.
Information has been received from a nurse concerning a 67 year old male patient with a history of cigarette smoking, chronic obstructive pulmonary disease, gastrooesophageal reflux disease and hyperlipidaemia who on 05-Dec-2007 was vaccinated with pneumococcal 23v polysaccharide vaccine (Lot #1383U) intramuscularly in the right arm.  Concomitant therapy included esomeprazole magnesium (Nexium), lovastatin (Lipivas (lovastatin)), tiotropium bromide (spiriva), albuterol inhaler and bupropion.  On 07-Dec-2007 the patient developed a fever and an injection site rash that was reddened, large, painful and radiated from the injection site to the elbow.  The patient went to the emergency room for treatment of a fever and was admitted until discharged on 08-Dec-2007.  The patient's white blood cell count was 23,000.  Treatment during hospitalization was unspecified and the patient's current status was unspecified.  Additional information has been requested.
Nausea with Flatulence; Flatulence; woke up Saturday morning with diarrhea.; she felt fatigue/explains this as feeling tired; groggy; Loss of appetite; Headache; This non-serious case was reported by a consumer via call center representative and described the occurrence of fatigue in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included type ii diabetes mellitus.   On 25-AUG-2023, the patient received the 1st dose of Shingrix (left deltoid). On 25-AUG-2023, less than a day after receiving Shingrix, the patient experienced fatigue (Verbatim: she felt fatigue/explains this as feeling tired) and groggy (Verbatim: groggy). On 26-AUG-2023, the patient experienced diarrhea (Verbatim: woke up Saturday morning with diarrhea), appetite lost (Verbatim: Loss of appetite) and headache (Verbatim: Headache). On 28-AUG-2023, the patient experienced nausea (Verbatim: Nausea with Flatulence) and flatulence (Verbatim: Flatulence).  The patient was treated with loperamide hydrochloride (Imodium). The outcome of the fatigue was not resolved and the outcome of the groggy was not reported and the outcome of the diarrhea, nausea and flatulence were resolved and the outcome of the appetite lost and headache were resolved (duration 24 hrs).   It was unknown if the reporter considered the fatigue, groggy, diarrhea, appetite lost, headache, nausea and flatulence to be related to Shingrix.     It was unknown if the company considered the fatigue, groggy, diarrhea, appetite lost, headache, nausea and flatulence to be related to Shingrix.   Additional Information: GSK receipt date: 29-Aug-2023 The patient called to report symptoms after receiving her 1st dose of Shingrix on Friday and states that the night of Shingrix vaccine administration she felt fatigue and explains this as feeling tiered and groggy.   Friday night she went to bed and woke up Saturday morning with diarrhea.   The patient stated that she took 3 doses of Imodium for 2 days and then diarrhea resolved.   Saturday, 3 days after the vaccine, she had a loss of appetite and headache that lasted for 24 hours.   The patient also experienced nausea with excessive flatulence during the night.  In August 2023, all symptoms were recovered except fatigue. Reviewed the package inset adverse event section with reporter.   The reporter stated that she had a call out to her physician right now. The reporter consented to follow-up.
I tested positive for COVID 10 days after receiving my first vaccination. First showed symptoms of Covid one week after vaccination but felt unwell 4 days after receiving vaccination.
Patient c/o nausea and headache/migraines for 1 week. continuing from Sunday 4/18/21 to present 4/24/21.  also complains of hard lump on arm at injection site which just manifest itself today 4/24/21
Started experiencing numbness in middle toes of left foot. Noticed it while I was reclined watching a television program and when I was exercising (walking). Numbness has progressively spread to other toes, and toes on the right foot.  Starting to experience numbness in the ball of left foot.
pt recvd vax; swelling, redness & inc warmth 3x6cm area around inject site;
Extra dose administered; This spontaneous report was received from an other health professional and a lawyer, referring to a 82 year old female patient with abstains from alcohol, abstains from recreational drugs and caffeine consumption. The patient was allergic to lisinopril and quinapril (cough). The patient's family medical history included father (died from pneumonia ), mother (renal failure, hypertension, died from snake bite), brother (diabetes, hypertension, died), sister (kidney transplant). The patient's medical history included cigarettes smoker and chicken pox. Historical vaccines included varicella vaccine. The patient's concomitant medication was not reported.   On 09-SEP-1999 the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) (dose, route, strength, batch/lot# and expiration date unknown). On 15-FEB-2005 the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) (dose, route, strength, batch/lot# and expiration date unknown). On 26-AUG-2019 the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) (dose 0.5ml, lot# R036943 has been verified to be a valid lot number, expiration date 09-APR-2020; route and strength unknown) in the left deltoid (extra dose administered).  The case is linked to case# US-009507513-1812USA001636 and US-009507513-2001USA006254 due to the same patient.; Sender's Comments:  US-009507513-1812USA001636: US-009507513-2001USA006254:
HER LEG IS DRAGGING. WHEN SHE HOLDS BOTH UP, THEY ARE UNEVEN. HER WALK IS UNSTEADY
Patient received his 1st Monovalent dose of Pfizer at 9:50am. A couple of minutes later during the observation period, patient said he was feeling anxious and a bit lightheaded. Patient was given another chair so he could put his legs up. Patient let RN know that he was going to pass out. Patient then fainted while sitting and was unconscious for a few second (about 15-30 seconds total) Patient was lowered onto floor carefully and regained consciousness. Patients BPM and BP was checked and he was monitored for about 30 minutes after. Patient then shared he was okay and left.
awoke w/nausea & severe h/a in back of head w/gen aching;called personal MD 2OCT97 @ 730AM who told pt to report to VAERS;
The patient had no other vaccine in 4 weeks and no other medications in 2 weeks. Patient was not covid tested post vaccination. The patient experienced muscle pain, fatigue, night sweats, sore arm on 31Jan2021.Therapeutic measures were not taken as a result of all events. The outcome of all event was recovered.  Follow-up attempts completed. No further information expected.
hives; bumps on back; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 30Mar2021 at 15:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies. Concomitant medications included vitamins (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via unspecified route of administration in the left arm on 02Mar2021 at 15:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 31Mar2021 at 08:00, approximately 30 hours after the second shot (as reported), the patient experienced severe allergic reaction (hives and bumps on back (allergic reaction)). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of adverse events included 200 mg of BENADRYL and 2% hydrocortisone. The clinical outcome of the events hives and bumps on back were recovering.   No follow-up attempts are needed. No further information is expected.
Patient developed transient uveitis within 48 hours of vaccine. She was seen by opthalomologist.  Uveitis lasted for 1 month with steroid treatment.  She also developed a transiently positive RPR
Dizziness, extreme fatigue, increased resting heart rate (above 85 bpm), high anxiety & large bruising at the injection site starting within 24 hours of injection. No fever recorded so far. Symptoms started getting worse about 3 days after injection and continue as of 4/9/21.
Mild fever (99.7F); Fatigue; Foggy-headed; Upset stomach; Headache; Felt very cold, could not get warm; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP-6955) via an unspecified route of administration in the left arm on 08Apr2021 at 10:00 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma, obesity and allergic to cephalosporins. Concomitant medications included estrogens conjugated, medroxyprogesterone acetate (PREMPRO), fluoxetine (MANUFACTURER UNKNOWN), bupropion (MANUFACTURER UNKNOWN) and fluticasone propionate (FLOVENT); all from unknown date for unknown indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 16Mar2021 at 10:00 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021 at 12:00 (26-hour post vaccine), the patient experienced felt very cold, could not get warm. On 09Apr2021 at 14:00 (28 hours post vaccine), the patient experienced upset stomach and headache. On 09Apr2021 at 16:00 (30 hours post vaccine), the patient experienced foggy-headed, mild fever (99.7F) and fatigue. On 09Apr2021, the patient underwent Body temperature and the result was mild fever (99.7F). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the event felt very cold, upset stomach, headache, foggy-headed, mild fever (99.7F) and fatigue was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Primary series does of 5-11 Pfizer COVID vaccine given instead of 5-11 Pfizer bivalent booster dose.
pain; fatigue; episode of cold sores; This case was reported by a other health professional via call center representative and described the occurrence of pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 28th May 2021, the patient received the 1st dose of Shingrix. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced pain, fatigue and cold sores. On an unknown date, the outcome of the pain and fatigue were unknown and the outcome of the cold sores was not recovered/not resolved.   It was unknown if the reporter considered the pain, fatigue and cold sores to be related to Shingrix.  Additional details were provided as follows: This case was reported by the patient himself, who was the physician. The age at vaccination was not reported. The patient received Shingrix and developed pain and fatigue. The health care professional clarified that she thought she was starting an episode of cold sores and was wondering if this constituted a contraindication for dose two. The reporter had no further details regarding the symptoms experienced.  The reporter to consented to follow up.
Approximately 45m - 60m, throat swelling, tingling mouth and lips. Went to ER and treated with prednisone, BENADRYL, ZYRTEC and PEPCID. Next day, symptoms came back with flushing and repeated meds.
adverse reaction; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (adverse reaction) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (adverse reaction). At the time of the report, VACCINATION COMPLICATION (adverse reaction) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
expired vaccine is stored on refrigerator on 27-Nov-2021 and then administered on 01-Dec-2021; 606 doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) and PRODUCT STORAGE ERROR (expired vaccine is stored on refrigerator on 27-Nov-2021 and then administered on 01-Dec-2021) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (expired vaccine is stored on refrigerator on 27-Nov-2021 and then administered on 01-Dec-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) and PRODUCT STORAGE ERROR (expired vaccine is stored on refrigerator on 27-Nov-2021 and then administered on 01-Dec-2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The vial was placed in the refrigerator on 27-Nov-2021.Vial did not undergo any temperature excursion. No adverse event was reported.  No treatment medications were reported.
Left deltoid increased warmth, redness, edema 3 inches x 5 inches.  Complained of itching.
Progressive pain and paresthesias (stinging and burning) in T1 dermatome ipsilateral side to vaccine admin.  Symptoms increased over the next 3 days, then subsided by 11/2/16.
On a monoclonal therapy and tested positive; On a monoclonal therapy and tested positive; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "On a monoclonal therapy and tested positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of drug ineffective, suspected covid-19.  Clinical Course: The patient stated that he already had the 4 vaccines and he was on a monoclonal therapy and tested positive. Reporter asked for how long could they get bivalent after being negative for COVID virus.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from a registered nurse referring to a patient of unknown age and gender. There was no pertinent medical history, concomitant medication or drug allergies/drug reactions reported. On 11-AUG-2015, the patient was vaccinated with ZOSTAVAX (1 ml, Lot#L011529, expiration date: 03-JUL-2016), which was improperly stored for 8 days. The outcome was unknown. This is one of several reports received from the same reporter. Additional information has been requested.
patient reported numbness in her upper deltoid muscle on the side of vaccination initially. After 5 minutes the patient reported feeling a little short of breath and that her heart rate felt fast. Patient remained alert and oriented throughout. Patient was given water and instructed to perform pursed lip breathing. When attempting to move patient to a private space, she reported weakness in her legs and required assistance to  transfer to a  wheel chair. 911 was called when patient reported trouble breathing that was not improving. Patient also reported a history of anxiety and congestive heart failure. Patient was transported to a local emergency department via ambulance for further evaluation.  Patient was transported away from our clinic at 10:15am.
heart raced 130 bpm; right arm went numb; bitter medicine taste; lips and tongue tingling; numbness of the lips; numbness of the throat; dry mouth; super thirsty; elevated blood pressure of 175/56; couldn't talk; shaking; terrible pain in chest and mid area; gassiness; headache; Nausea; A spontaneous report was received from a Consumer concerning a 67 year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced  events like bitter medicine taste in her mouth, lips and tongue tingling, numbness of the lips and throats, dry mouth, super thirsty, heart raced 130bpm, elevated blood pressure of 175/56, couldn't talk, shaking, terrible pain in chest and mid area, nausea, right arm went numb, gassiness, and headache.  The patient's medical history provided included Lupus and Sjogren's. No relevant concomitant medications were reported.     On 12-Feb-2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot/batch: 013M20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.   On 12 Feb 2021, The patient experienced the events of bitter medicine taste in her mouth, lips and tongue tingling, numbness of the lips and throats, dry mouth, super thirsty, heart raced 130bpm, elevated blood pressure of 175/56, couldn't talk, shaking, terrible pain in chest and mid area, nausea, right arm went numb, gassiness, and headache.  Laboratory details were not provided.   No treatment information was provided.    Action taken with mRNA-1273 in response to the events was not reported.    The outcome of the events of bitter medicine taste in her mouth, lips and tongue tingling, numbness of the lips and throats, dry mouth, super thirsty, heart raced 130bpm, elevated blood pressure of 175/56, couldn't talk, shaking, nausea, right arm went numb, resolved on 12 Feb 2021.  The outcome of the event headaches was resolved on 13 Feb 2021.  At the time of the report the events of chest pain and gassiness were ongoing.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  The patient's medical history of  Lupus and Sjogren's can be contributing factor. Further information has been requested.
Pt dvlped atrophic dermatitis at site of injection. 4 cm x 4 1/2 cm darkened area dvlped-hypersensitive to palpation w/ discomfort.
This case was reported by a nurse and described the occurrence of yellow skin in an adult male subject who was vaccinated with hep B vaccine recombinant (Engerix B) for prophylaxis. On an unspecified date before 13May05, the subject received the first dose of Engerix B. At an unspecified time following the first dose of Engerix B, on an unspecified date before 13May05, the subject experienced yellowing of the skin. The nurse reported that the subject never contacted a physician and it was never evaluated by a physician. The yellowing of the skin resolved on an unspecified date on or before 13May05. Yellowing to the skin was assessed as medically serious by manf.
This spontaneous report was received from a physician via a company representative, referring to a patient of unknown age and gender. No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided. On 12-MAR-2015, the patient was vaccinated with the improperly stored dose of PNEUMOVAX 23 lot number K009106 with expiration date of 25-FEB-2016 (dose number, route of administration and anatomical location were not provided), which was stored at -2.77 Celsius Degrees for 528 hours. The type of excursion was refrigerator. No adverse effects were reported. No product quality complaint was involved. This is one of several cases from the same reporter. Additional information has been requested.
It was discovered post-hoc that the patient was given his second dose at the wrong time interval. He received the 2nd dose of Pfizer 14 days after his first dose.
I am experiencing muscle pain, chest pain, heart palpitations,  faint and nearly blacking out when I stand, weak, and fatigued.  Headache and head pressure. Soreness in left arm in injection site.